Rho-associated protein kinase 1 (ROCK1) has been reported to be overexpressed in many types of tumors, but its role in urothelial bladder cancer is poorly understood. The study aims to investigate the role of ROCK1 in urothelial bladder cancer and explored the underlying mechanism. Protein and mRNA levels of ROCK1 were detected in 64 urothelial bladder cancer patients using western blot, immunohistochemistry and qRT-PCR. Relationships between ROCK1 expression and clinicopathological factors and survival rate were analyzed. ROCK1 was silenced by shRNA in multiple urothelial bladder cancer cells to explore its function and underlying mechanism. ROCK1 expression was significantly increased in tumor tissues compared with the paired adjacent healthy tissues of patients. Higher ROCK1 expression of tumor tissues positively correlated with poor prognosis of patients (p = 0.0435). ROCK1 silence significantly inhibited cell proliferation and colony formation, and enhanced activation of apoptotic pathway in urothelial bladder cancer cells. High ROCK1 expression predicts poor prognosis of urothelial bladder cancer. ROCK1 silence inhibit cell proliferation and promote apoptosis, which may be of value as a therapeutic target for bladder cancer treatment.

据报道，Rho 相关蛋白激酶 1 (ROCK1) 在多种类型的肿瘤中过度表达，但其在膀胱尿路上皮癌中的作用尚不清楚。该研究旨在探讨ROCK1在膀胱尿路上皮癌中的作用并探讨其潜在机制。使用蛋白质印迹、免疫组织化学和 qRT-PCR 检测 64 名膀胱尿路上皮癌患者中 ROCK1 的蛋白和 mRNA 水平。分析ROCK1表达与临床病理因素及生存率的关系。在多个膀胱尿路上皮癌细胞中通过 shRNA 沉默 ROCK1，以探索其功能和潜在机制。与患者配对的邻近健康组织相比，ROCK1 表达在肿瘤组织中显着增加。p  = 0.0435）。ROCK1沉默显着抑制膀胱尿路上皮癌细胞的细胞增殖和集落形成，并增强凋亡途径的激活。ROCK1 高表达预示膀胱尿路上皮癌预后不良。ROCK1沉默抑制细胞增殖并促进细胞凋亡，这可能作为膀胱癌治疗的治疗靶点具有价值。